NCT05259657: Lymfit

Feasibility, Acceptability, and Preliminary Effects of Lymfit

Completed NA Last updated 5 April 2024

What this trial tests

NA trial testing Lymfit Intervention in Cancer Survivors in 26 participants. Completed in 1 December 2023.

Timeline

1 February 2022

Primary endpoint
1 March 2023

1 December 2023

Quick facts

Lead sponsor	McGill University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	26
Start date	1 February 2022
Primary completion	1 March 2023
Estimated completion	1 December 2023
Sites	1 location across Canada

Drugs / interventions tested

• Lymfit Intervention
• Wait-list control

Conditions studied

• Cancer Survivors — all drugs for Cancer Survivors →
• Lymphoma — all drugs for Lymphoma →

Sponsor

McGill University

Who can join

Adults 18 to 39, any sex, with Cancer Survivors or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Lymphoma is one of the most diagnosed cancers in young adults aged 18 to 39. Lymphoma is highly treatable, and the survival rate is often high. Yet, cancer treatments can be toxic, and their side effects can negatively impact the quality of life among cancer survivors. The current research suggests that being active after treatment can improve cancer outcomes. For instance, reducing cancer-related fatigue, anxiety, depression, and improving sleep quality and survival. Physical activities can greatly improve the quality of life after cancer treatment.

Knowledge Gap: Young adults are unique from cancer patients of other age groups. Young adults need stage-of-life-specific, person-centred cancer and survivorship care. Despite knowing that exercise is beneficial in improving cancer outcomes, cancer survivors' engagement and adherence to exercise guidelines remain poor. It is crucial to develop an effective intervention that can motivate lymphoma patients to be active after treatment.

Purposes: Our study team developed a behavioural change intervention named LymFit. The LymFit intervention involves a personalized exercise program, bi-weekly kinesiology follow-ups, and the use of activity trackers. The aim of this study is to test if the design of the intervention is feasible and acceptable. The investigators also aim to test if the intervention is able to promote exercise motivation among young adult lymphoma survivors.

Implications: This 12-week pilot study examines the implementation strategies and clinical relevance of a behavioural change intervention targeting young adult lymphoma survivors. The study results have the potential to map out the optimal design of an effective physical activity intervention in improving cancer outcomes, and optimize post-cancer treatment care coordination among health professionals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Pilot Randomized Controlled Trial of <i>Lymfit</i>: A Theory-Guided Exercise Intervention for Young Adults with Lymphoma.
   Tock WL, Johnson NA, Andersen RE, Salaciak M, et al · · 2024 · cited 3× · PMID 38891177 · DOI 10.3390/healthcare12111101